Hansa Biopharma
Blood & Organ Banks · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen 22, Lund, Skane, 223 63, Sw...Phone Number
+46 46165670Website
www.hansabiopharma.comRevenue
$19.5 MillionStock Symbol
HNSAIndustry
ZI Rank: 5
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
68
8
4
5
5
About Hansa Biopharma
Hansa Biopharma AB is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative immunomodulatory therapies. The company focuses on addressing unmet medical needs in rare diseases and transplantation by leveraging its expertise in biotechnology and protein engineering. Its core mission centers on discovering, developing, and delivering therapies that modify the immune system, with a particular emphasis on biologic treatments designed to improve patient outcomes. Hansa Biopharma combines cutting-edge research with clinical development and regulatory expertise to bring novel therapies from the laboratory to the clinic, positioning itself as a leader in the field of specialized immunology and rare disease therapeutics.Explore more
Hansa Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hansa Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Hansa Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Hansa Biopharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Hansa Biopharma is spiking on competitors!
Product Launch: Get notified when Hansa Biopharma launches new products
Funding: Get notified immidiatlly once Hansa Biopharma has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Hansa Biopharma had a recent Job posting/layoffs
Earning: See what the market has to say on Hansa Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hansa Biopharma
Recommended Actions
Reach out to Masked Content who joined Hansa Biopharma as Masked Content
Find 2 more new buyers
Compare Similar Companies to Hansa Biopharma
Compare insights from companies similar to Hansa Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Hansa Biopharma is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Hansa Biopharma is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Hansa Biopharma.
Hansa Biopharma financials insights
Gather financial insights about Hansa Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$121M
2022
Other Financing Round
$70M
2026
Debt
$30M
Hansa Biopharma Tech Stack
A closer look at the technologies used by Hansa Biopharma
Most Recent Scoops
Open Position
Open Position
Project
Hansa Biopharma has announced plans to launch imlifidase in the US in Q1 2027, subject to FDA approval, with the company targeting launch readiness at the PDUFA date.
Pharmaceuticals
Hiring Plans
Hansa Biopharma has announced that headcount totaled 153 as of Q2 2026, up from 140 in Q2 2025 and 122 in Q1 2026, reflecting hiring in preparation for the expected US market launch, and not yet reflecting the anticipated transfer of personnel to SERB related to the out-licensing transaction.
Hiring Plans, Recruitment, HR Operations
Earnings
Earnings, Finance
Hansa Biopharma News & Media
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call July 22, 2026 8:00 AM EDTCompany ParticipantsRenee Aguiar-Lucander - Chief Executive OfficerMonika...Hansa Biopharma participating in Wedbush PacGrow Renal Summit
LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with...Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of...Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day June 25, 2026 9:00 AM EDTCompany ParticipantsRenee Aguiar-Lucander - Chief Executive OfficerRichard...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hansa Biopharma
Sign Up For FreeTo access detailed company insights
Hansa Biopharma AB is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative immunomodulatory therapies. The company focuses on addressing unmet medical needs in rare diseases and transplantation by leveraging its expertise in biotechnology and protein engineering. Its core mission centers on discovering, deve... Read More
